WO2008099883A1 - 肝臓癌治療剤 - Google Patents
肝臓癌治療剤 Download PDFInfo
- Publication number
- WO2008099883A1 WO2008099883A1 PCT/JP2008/052443 JP2008052443W WO2008099883A1 WO 2008099883 A1 WO2008099883 A1 WO 2008099883A1 JP 2008052443 W JP2008052443 W JP 2008052443W WO 2008099883 A1 WO2008099883 A1 WO 2008099883A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liver cancer
- cancer
- therapeutic agent
- liver
- rifampicin
- Prior art date
Links
- 201000007270 liver cancer Diseases 0.000 title abstract 6
- 208000014018 liver neoplasm Diseases 0.000 title abstract 6
- 239000003814 drug Substances 0.000 title abstract 3
- 229940124597 therapeutic agent Drugs 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 abstract 3
- 229960001225 rifampicin Drugs 0.000 abstract 3
- 230000001394 metastastic effect Effects 0.000 abstract 2
- 206010061289 metastatic neoplasm Diseases 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 abstract 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000009545 invasion Effects 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000005228 liver tissue Anatomy 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-034960 | 2007-02-15 | ||
| JP2007034960A JP2010111582A (ja) | 2007-02-15 | 2007-02-15 | リファンピシンを成分とする肝臓癌治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008099883A1 true WO2008099883A1 (ja) | 2008-08-21 |
Family
ID=39690110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/052443 WO2008099883A1 (ja) | 2007-02-15 | 2008-02-14 | 肝臓癌治療剤 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP2010111582A (zh) |
| CN (2) | CN102793702A (zh) |
| WO (1) | WO2008099883A1 (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004075665A (ja) * | 2002-06-21 | 2004-03-11 | Japan Science & Technology Corp | アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法 |
-
2007
- 2007-02-15 JP JP2007034960A patent/JP2010111582A/ja active Pending
-
2008
- 2008-02-14 WO PCT/JP2008/052443 patent/WO2008099883A1/ja active Application Filing
- 2008-02-14 CN CN2012102751684A patent/CN102793702A/zh active Pending
- 2008-02-14 CN CNA200880005174XA patent/CN101610771A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004075665A (ja) * | 2002-06-21 | 2004-03-11 | Japan Science & Technology Corp | アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法 |
Non-Patent Citations (1)
| Title |
|---|
| KATO T. ET AL.: "Shizen Taishuku shita Haikekkaku Gappei Haigan no Ichirei", HAIGAN, vol. 45, no. 2, 20 April 2005 (2005-04-20), pages 127 - 132 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102793702A (zh) | 2012-11-28 |
| JP2010111582A (ja) | 2010-05-20 |
| CN101610771A (zh) | 2009-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2008339918A1 (en) | Medicament for the treatment of cancer of the pancreas | |
| WO2008124660A3 (en) | Methods and compositions for the treatment of cancer | |
| WO2009156484A3 (en) | Organic compounds | |
| WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
| WO2008131000A3 (en) | 7-substituted indole mcl-1 inhibitors | |
| WO2007146957A3 (en) | Ror1 as a therapeutic target for lung cancer | |
| EP2093237A4 (en) | ANTICANCER AGENT COMPRISING ANTI-HB-EGF ANTIBODY AS ACTIVE INGREDIENT | |
| WO2007044084A3 (en) | Heterocyclic inhibitors of mek and methods of use thereof | |
| WO2007120747A3 (en) | Transdermal methods and systems for the delivery of anti-migraine compounds | |
| DK1868579T3 (da) | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer | |
| WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
| WO2007143597A3 (en) | Organic compounds | |
| MX2010006933A (es) | Composiciones y metodos para reducir o prevenir la deshidratación de la piel. | |
| WO2007081751A9 (en) | Compositions and methods for the treatment of cancer | |
| NZ579478A (en) | Epha3 antibodies for the treatment of solid tumors | |
| ZA201203689B (en) | A pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compound and a sytoplasmic glycolysis reduction agent | |
| WO2007011759A3 (en) | Inhibitors of mitotic kinesin | |
| WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
| HK1133642A1 (en) | Azaadamantane ester and carbamate derivatives and methods of use thereof | |
| WO2008112290A3 (en) | Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer | |
| WO2008008700A3 (en) | Substituted cyclopentane derivatives as therapeutic agents | |
| WO2012024399A3 (en) | Compositions comprising paulownin and/or paulownia extracts and uses thereof | |
| WO2013019093A3 (en) | Novel aniline derivatives and use thereof | |
| WO2012018932A3 (en) | Compounds and compositions for mitigating tissue damage and lethality | |
| TW200738134A (en) | Fungicidal active compound combination |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WWE | Wipo information: entry into national phase |
Ref document number: 200880005174.X Country of ref document: CN |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08711285 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08711285 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |